Company news
SELLAS Life Sciences Group, Inc. news in 2020
SELLAS Life Sciences Group, Inc.'s news releases, calls and decks from 2020, newest first.
SELLAS Announces Promising Initial Clinical Data for Galinpepimut-S (GPS) in Combination with Checkpoint Inhibitors in Two Solid Tumor Indications
December 20, 2020
SELLAS Strengthens Year-End Balance Sheet with Addition of Approximately $30.5 Million
December 16, 2020
SELLAS Announces Pricing of $16.2 Million Registered Direct Offering
December 12, 2020
SELLAS Announces Positive Follow-up Data from the Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In-Situ of the Breast
December 10, 2020
SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China
December 6, 2020
SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results
November 12, 2020
SELLAS Receives IMPD Approval from the French Regulatory Authority for its Pivotal Phase 3 REGAL Study of Galinpepimut-S in Patients with Acute Myeloid Leukemia
September 8, 2020
SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2020 Financial Results
August 12, 2020
SELLAS Life Sciences Announces $9.2 Million Private Placement Priced At-The-Market
July 30, 2020